Speciality: Pediatrics
Description:
A warm welcome to all the medical professionals in this interesting session on Arthritis and children: What is JIA?
Juvenile idiopathic arthritis (JIA) is the most common type of arthritis affecting children and adolescents under the age of 16. It is an autoimmune condition in which the body’s immune system mistakenly attacks its own tissues, leading to inflammation in the joints. This results in symptoms such as joint pain, swelling, stiffness, and reduced mobility. JIA can affect one or multiple joints and, in some cases, may also involve other organs, such as the eyes or skin.
There are several subtypes of JIA, each with different characteristics and levels of severity. While the exact cause is unknown, a combination of genetic and environmental factors is believed to play a role. Early diagnosis and treatment are crucial in managing JIA, as they can prevent long-term joint damage and improve the child’s quality of life. Treatment typically includes medications like NSAIDs, DMARDs, or biologics, along with physical therapy to maintain joint function and mobility.
Therefore, get an overall knowledge of arthritis and children: what is JIA?
See More Webinars @ Hidoc Webinars
1.
While most cancer screenings won't prolong lives, there are still good reasons to continue screening.
2.
High Fruit, Veggie Diet Tied to Early-Onset Lung Cancer?
3.
Cancer Diagnoses Slow to Recover From Effects of COVID Pandemic
4.
The pandemic had little impact on mental health symptoms.
5.
How breast tissue density affects your risk of breast cancer
1.
Uncovering Breast Cancer: The Power of Early Stage Ultrasound
2.
Deciphering FFR: A Comprehensive Guide to Understanding Its Meaning
3.
The Miracle of Tenecteplase: How This Drug Is Saving Lives
4.
Cancer-Keeper Genes: Novel Therapeutic Targets for Disrupting Tumor Maintenance
5.
Patient-Centric Approaches in Hematology: Integrating Individualized Care into Modern Clinical Practice
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
2.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
5.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation